Anika Therapeutics (ANIK) Common Equity (2010 - 2026)
Anika Therapeutics (ANIK) posted quarterly Common Equity of $137.3 million for Q2 2026, down 7.04% year-over-year from $147.7 million in Q2 2025, and up 2.52% quarter-over-quarter from $133.9 million in Q1 2026.
Anika Therapeutics (ANIK) Common Equity (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Common Equity for 17 consecutive years, with $137.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Common Equity fell 7.04% year-over-year to $137.3 million; the TTM figure through Jun 2026 stood at $137.3 million (down 7.04% YoY), while the FY2025 annual figure was $143.5 million, down 6.83% from the prior year.
- Common Equity rose to $137.3 million in Q2 2026 per ANIK's latest filing, from $133.9 million in the prior quarter.
- Across five years, Common Equity topped out at $286.2 million in Q2 2022 and bottomed at $133.9 million in Q1 2026.
- Historically, Common Equity has averaged $210.4 million across 5 years, with a median of $209.4 million in 2024.
- Annual changes were most pronounced in 2022 — Common Equity grew 3.3% — and 2024, when it plunged 33.5%.
- Anika Therapeutics' Common Equity stood at $285.6 million in 2022, then decreased by 25.67% to $212.3 million in 2023, then declined by 27.45% to $154.0 million in 2024, then declined by 6.83% to $143.5 million in 2025, then dropped by 4.31% to $137.3 million in 2026.
- Business Quant data shows ANIK's Common Equity at $137.3 million in Q2 2026, $133.9 million in Q1 2026, and $143.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 4.05 Bn |
| 10 | Anika Therapeutics | 282.86 Mn | 244.45 Mn | 21.24 Mn | 137.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 137.28 Mn |
| Mar 31, 2026 | 133.90 Mn |
| Dec 31, 2025 | 143.47 Mn |
| Sep 30, 2025 | 146.81 Mn |
| Jun 30, 2025 | 147.67 Mn |
| Mar 31, 2025 | 148.40 Mn |
| Dec 31, 2024 | 153.99 Mn |
| Sep 30, 2024 | 179.86 Mn |
| Jun 30, 2024 | 210.34 Mn |
| Mar 31, 2024 | 208.54 Mn |
| Dec 31, 2023 | 212.27 Mn |
| Sep 30, 2023 | 270.49 Mn |
| Jun 30, 2023 | 274.02 Mn |
| Mar 31, 2023 | 277.59 Mn |
| Dec 31, 2022 | 285.56 Mn |
| Sep 30, 2022 | 284.94 Mn |
| Jun 30, 2022 | 286.15 Mn |
| Mar 31, 2022 | 285.79 Mn |
| Dec 31, 2021 | 287.09 Mn |
| Sep 30, 2021 | 290.06 Mn |